ent-dextilidine and Chronic-Disease

335 patients (51% female, 49% male, mean age 56 years) with chronic pain and multimorbidity have been included in a multi-center 2-years' study with slow release Tilidine/Naloxone for efficacy and safety which included detailed laboratory examinations. 316 patients had already been treated with analgesics. 159 patients (47.5%) finished the study as planned, 176 patients finished the study earlier.. Parameters of quality of life such as persistent pain, sleep, mood and activity have improved. Tolerance has not been observed. In 85 patients (25%) adverse events had occurred (nausea, vomiting, dizziness) which are related to the study-medication. Constipation was documented in only 4 patients. After 2 years of therapy with Tilidine/Naloxone there has been no relevant changes in laboratory findings. There has been no sign of organ damage or interactions with concomitant medication.. Tilidine/Naloxone is an effective and safe analgesic (WHO II) suitable for the longterm treatment of patients with chronic pain.

Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Comorbidity; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Long-Term Care; Male; Middle Aged; Naloxone; Pain; Pain Measurement; Quality of Life; Tilidine; Treatment Outcome

The transdermal 7-day buprenorphine matrix patch provides a constant and user-friendly pain management when chronic musculoskeletal pain requires opioids. This analysis of clinical routine data evaluated the benefit of this treatment for patients previously receiving oral long-term treatment with weak opioids alone. Data of 310 patients previously treated with tramadol or tildate/naloxone and part of a multicentre observational study with 3295 patients were analyzed. In 89.7% of the 310 patients oral treatment with weak opioids was replaced by the 7-day buprenorphine patch due to insufficient analgesia. During treatment with the 7-day buprenorphine patch there was a clinically significant decrease of the mean pain intensity at rest during the day from 5.7 to 2.9, on physical effort during the day from 7.3 to 3.8 and at night from 5.2 to 2.3 (11-point NRS scale, p < or = 0.001). In addition, quality of life aspects such as mobility, self-reliance and quality of sleep improved, which are relevant for individual patient satisfaction with pain management. For patients with previous long-term tramadol or tilidate/naloxone treatment the switch to the 7-day buprenorphine matrix patch proved to be effective and safe for the management of chronic pain. The user-friendly 7-day application interval contributes to improving compliance and a reducing exposure to tablets.

Topics: Activities of Daily Living; Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chronic Disease; Drug Substitution; Female; Germany; Humans; Long-Term Care; Male; Middle Aged; Naloxone; Pain; Pain Measurement; Prospective Studies; Quality of Life; Tilidine; Tramadol

Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naloxone; Narcotic Antagonists; Pain; Tilidine; Time Factors

Topics: Analgesics, Opioid; Chronic Disease; Delayed-Action Preparations; Humans; Musculoskeletal Diseases; Pain; Pain Measurement; Tilidine; Treatment Outcome

Topics: Aged; Analgesics, Opioid; Arthralgia; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Middle Aged; Musculoskeletal Diseases; Naloxone; Osteoarthritis; Pain Measurement; Patient Satisfaction; Tilidine; Treatment Outcome

Topics: Analgesics, Opioid; Chronic Disease; Cross-Sectional Studies; Health Surveys; Humans; Pain; Pain Measurement; Tilidine; Treatment Outcome

50 patients with incurable chronic pain states were treated for a period of between six months and 14 years (median: 31 months) with tilidine-naloxone, and the results of tumor recorded. Amelioration of pain was achieved in an average of 60.7% of the cases. The 16 patients of this series suffering from neuropathic pain who received a somewhat lower dose responded equally as well (60.3% amelioration) as the overall group. In 24 patients suffering from pain, the daily dose remained unchanged throughout the course of treatment, had to be increased in 19, and was reduced in seven patients. In two patients, acceptable side-effects were indicated; in no case were there any signs of drug-induced organic damage.. The results show that tilidine-naloxone is a highly effective opioid analgesic with a remarkably favorable benefit-risk ratio for use in long-term treatment.

Topics: Adult; Aged; Analgesics, Opioid; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Pain; Pain Measurement; Tilidine